Extrawell Pharmaceutical Holdings Ltd. has released its annual results for the year ended 31 March 2025. The company reported a consolidated profit attributable to owners of approximately HK$222.6 million, marking a significant turnaround from a loss of about HK$162.9 million in the previous year. This represents an increase of approximately HK$385.6 million year-over-year. The Group's revenue from continuing operations, which includes the manufacturing and trading of pharmaceutical products, totaled HK$55.4 million, slightly down from HK$59.1 million in the prior year. Specifically, the manufacturing segment generated HK$55.4 million, while trading contributed HK$24,000. Despite a loss of HK$0.1 million from discontinued operations, the overall financial performance was bolstered by positive changes in the fair value of convertible bonds amounting to approximately HK$254.9 million, compared to a loss of HK$133.0 million the previous year. However, this was partially offset by an increase in interest expenses on convertible bonds, which rose by HK$3.4 million. The Group continues its focus on the manufacturing and trading business segments as part of its ongoing operations. No specific outlook or guidance for future performance was provided in the announcement.